Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darbinurad
- Development stage
- Phase 2
- Lead developer
- InventisBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Darbinurad (D-0120) is an oral, selective small molecule inhibitor of the uric acid transporter 1 (URAT1), currently under development by InventisBio for the treatment of gout and hyperuricemia. By inhibiting URAT1 in the kidneys, the drug reduces the reabsorption of uric acid from the renal tubules back into the bloodstream, thereby increasing urinary uric acid excretion and lowering serum uric acid levels. It has completed Phase 2b clinical trials in China and the United States, demonstrating its potential as a targeted therapy for metabolic disorders associated with elevated uric acid.
- Other names
- darbinuradD-0120D0120D 0120D 0120-NAD0120-NAD-0120-NA
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on darbinurad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darbinurad.